BACKGROUND: It has recently been suggested that recombinant FSH administration may result in an increased risk of venous thrombosis. An open-label, randomized, controlled trial was carried out to compare the impact of urinary and recombinant FSH on haemostasis. METHODS: Fifty infertile women were randomized, using a random number generator on a personal computer, to receive either highly puri®ed urinary FSH (u-hFSH) or recombinant human FSH (r-hFSH); a starting dose of 150 IU. Human chorionic gonadotrophin 10000 IU was administered once there was at least one follicle >18 mm. The luteal phase was supported with progesterone 50 mg/ day for at least 15 days. Fifty normally menstruating women were recruited as controls. Repeated measurements of estradiol, progesterone, prothrombin time (PT) expressed as INR, activated partial thromboplastin time (APTT) ratio, ®brinogen (FBG), factor VIII (FVIII), normalized activated protein C ratio (nAPC ratio), antithrombin III activity (AT), protein C activity (PC), protein S activity (PS), tissue-type plasminogen activator antigen (t-PA), type 1 plasminogen activator inhibitor (PAI), prothrombin fragments 1+2 (F1+2), were performed during both hyperstimulated and natural cycles, and at onset of the following menstruation or at 8 weeks of pregnancy. RESULTS: At the end of gonadotrophin administration PT INR increased in the u-hFSH group, while AT and t-PA signi®cantly decreased. In the patients treated with r-hFSH, only F1+2 signi®cantly decreased. No signi®cant changes were observed in the control group. In the luteal phase FBG increased signi®cantly in all groups. In the uhFSH group no other signi®cant changes were noted compared to pre-ovulatory values, while compared to baseline values AT, PS and t-PA signi®cantly decreased. In the r-hFSH group during the luteal phase PT INR signi®cantly decreased, but did not differ from baseline levels. Other parameters such as FBG, FVIII, t-PA, rose signi®cantly, but only FVIII and FBG values were signi®cantly higher than baseline levels. In the women who became pregnant a signi®cant increase in t-PA and a signi®cant decrease in PS at the midluteal phase were observed. After one month all the haemostatic parameters returned to baseline value if pregnancy failed to occur, while in the pregnant women a signi®cant increase in FVIII and a signi®cant decrease in PS were observed. CONCLUSIONS: Ovarian stimulation with recombinant FSH does not in¯uence coagulation and ®brinolysis signi®cantly, as already reported for urinary gonadotrophins. The moderate changes induced by both treatments are no longer detectable after 4 weeks.

Impact of highly purified urinary FSH and recombinant FSH on haemostasis: an open-label, randomized, controlled trial

RICCI, GIUSEPPE;GUASCHINO, SECONDO
2004

Abstract

BACKGROUND: It has recently been suggested that recombinant FSH administration may result in an increased risk of venous thrombosis. An open-label, randomized, controlled trial was carried out to compare the impact of urinary and recombinant FSH on haemostasis. METHODS: Fifty infertile women were randomized, using a random number generator on a personal computer, to receive either highly puri®ed urinary FSH (u-hFSH) or recombinant human FSH (r-hFSH); a starting dose of 150 IU. Human chorionic gonadotrophin 10000 IU was administered once there was at least one follicle >18 mm. The luteal phase was supported with progesterone 50 mg/ day for at least 15 days. Fifty normally menstruating women were recruited as controls. Repeated measurements of estradiol, progesterone, prothrombin time (PT) expressed as INR, activated partial thromboplastin time (APTT) ratio, ®brinogen (FBG), factor VIII (FVIII), normalized activated protein C ratio (nAPC ratio), antithrombin III activity (AT), protein C activity (PC), protein S activity (PS), tissue-type plasminogen activator antigen (t-PA), type 1 plasminogen activator inhibitor (PAI), prothrombin fragments 1+2 (F1+2), were performed during both hyperstimulated and natural cycles, and at onset of the following menstruation or at 8 weeks of pregnancy. RESULTS: At the end of gonadotrophin administration PT INR increased in the u-hFSH group, while AT and t-PA signi®cantly decreased. In the patients treated with r-hFSH, only F1+2 signi®cantly decreased. No signi®cant changes were observed in the control group. In the luteal phase FBG increased signi®cantly in all groups. In the uhFSH group no other signi®cant changes were noted compared to pre-ovulatory values, while compared to baseline values AT, PS and t-PA signi®cantly decreased. In the r-hFSH group during the luteal phase PT INR signi®cantly decreased, but did not differ from baseline levels. Other parameters such as FBG, FVIII, t-PA, rose signi®cantly, but only FVIII and FBG values were signi®cantly higher than baseline levels. In the women who became pregnant a signi®cant increase in t-PA and a signi®cant decrease in PS at the midluteal phase were observed. After one month all the haemostatic parameters returned to baseline value if pregnancy failed to occur, while in the pregnant women a signi®cant increase in FVIII and a signi®cant decrease in PS were observed. CONCLUSIONS: Ovarian stimulation with recombinant FSH does not in¯uence coagulation and ®brinolysis signi®cantly, as already reported for urinary gonadotrophins. The moderate changes induced by both treatments are no longer detectable after 4 weeks.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11368/1695360
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 18
social impact